GIVLAARI® (givosiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of adults with acute hepatic porphyria (AHP). This medication targets aminolevulinate synthase 1 (ALAS1) to reduce the accumulation of neurotoxic intermediates and is administered as a subcutaneous injection once monthly.
Product Designer
Engineering Manager
Backend Developer
Product Manager
Simplify patient referrals and offer advanced treatment options with our infusion partnership program.
There may be a better way to manage your condition – explore infusion therapy.